MedTrace Logo

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal Failure

NCT01453816 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-07-21

No results posted yet for this study

Summary

The intent of this clinical study is to answer the questions:

1. Is the proposed treatment safe
2. Is treatment effective in improving the disease pathology of patients with Renal Failure and clinical outcomes

Conditions

  • Renal Failure

Interventions

PROCEDURE

Harvesting and Isolation of Stem cells

Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.

Sponsors & Collaborators

  • Instituto de Medicina Regenerativa

    collaborator INDUSTRY

  • Ageless Regenerative Institute

    lead INDUSTRY

Principal Investigators

  • Rigoberto Pallares, MD · Instituto de Medicina Regenerativa

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2014-12-31
Completion
2015-06-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01453816 on ClinicalTrials.gov